Absstract of: US2024158486A1
Methods of treating, preventing and/or retarding the progression of cognitive decline, in human subjects having a disease characterized by deposition of Aβ in the brain including Alzheimer's disease, Down's syndrome, and cerebral amyloid angiopathy, using anti-N3pGlu Aβ antibodies.
Absstract of: US2024159777A1
This invention provides methods for determining whether a subject has a condition correlative with a matrix effect comprising (a) admixing (i) a suitably diluted sample of a suitable fluid from the subject and (ii) a suitable amount of a labeled molecule, wherein the labeled molecule is subject to a matrix effect with respect to the suitable fluid in a subject afflicted with the condition, and (b) after a suitable duration under suitable conditions, determining the amount of matrix-unaffected labeled molecule present in the resulting admixture, wherein the subject is afflicted with the condition if the amount of matrix-unaffected labeled molecule determined in step (b) correlates with a positive control for the condition, and wherein the subject is not afflicted with the condition if that amount correlates with a negative control for the condition. This invention also provides related methods, kits, and compositions. The present methods and kits are particularly useful for predicting the onset of neurodegenerative disorders such Alzheimer's disease and Parkinson's disease.
Absstract of: US2024156342A1
Described herein is the use of a visible near infrared (VNIR) hyperspectral imaging system as a non-invasive diagnostic tool for early detection of Alzheimer's disease (AD). Also described herein is the use of a VNIR hyperspectral imaging system in high throughput screening of potential therapeutics against AD.
Absstract of: AU2022354161A1
The invention relates to skin biomarkers, and in particular, to skin biomarkers for diagnosing and prognosing neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, as well as diagnostic and prognostic methods and kits for these conditions. The invention also provides methods of treating neurodegenerative disorders. The invention further provides the use of biomarkers in the skin for skin aging (biological & chronological), and kits for detecting and quantifying skin aging, and also methods for treating, preventing or slowing down skin aging.
Absstract of: AU2022341967A1
The disclosure provides quinoline and quinazoline derivative compounds and pharmaceutical compositions thereof. These compounds inhibit the interactions between GAG- binding amyloid peptides (GBAPs) and heparan sulfate glycosaminoglycans (HS-GAGs) and thus may be useful as therapeutics for the treatment and prevention of neurodegenerative diseases associated with amyloidosis, for example Alzheimer's Disease, and for other amyloid disorders. The present disclosure further provides methods of treatment and prevention of neurodegenerative and amyloid diseases, and methods for identifying small organic molecule compounds that can inhibit the interaction of glycosaminoglycans (GAGs) with GAG-binding amyloid peptides (GBAPs).
Absstract of: CA3225302A1
Disclosed herein are method of diagnosing, selecting, monitoring, and treating subjects with Alzheimer's disease (AD) or suspected of having AD or another disorder associated with amyloid accumulation in the brain.
Absstract of: WO2023283021A1
Diagnostic microarray devices, kits, and methods of treating or reducing the occurrence of various conditions or diseases are disclosed, wherein the conditions or diseases include (but are not limited to) periodontal disease, Alzheimer's disease, cardiovascular disease, arthritis, and adverse pregnancy outcomes. The devices, kits, and methods utilize an analysis of single nucleotide polymorphisms (SNPs) from various interleukins.
Absstract of: AU2022313196A1
A method of assaying for the presence of Alzheimer's disease (AD) in a living human subject using a serum or plasma sample preparation from that human subject is disclosed. In one aspect, the presence of an about 90 kDa filamin A (FLNA) polypeptide fragment in a sample preparation indicates that the sample donor likely had AD. More preferably, a ratio of the amount of that about 90 kDa FLNA polypeptide fragment to the amount of full length (about 280 kDa) FLNA protein in the sample preparation is determined. If that ratio is about 10 to about 2000, the donor likely had AD, whereas if that ratio is about 0.005 to about 5, the donor likely did not have AD. A method for determining the treatment prognosis of a living human subject presumed to have Alzheimer's disease (AD), a system and kit for carrying out the assays are also contemplated.
Absstract of: CN117377777A
The present invention relates to single nucleotide polymorphisms (SNPs) based on chromosome 2, a 2: 10 < 7 >, 510 < 000 >-10 < 7 >, 540 < 000 > locus (as disclosed in genomic reference association human genome construction 37 (GRCh37)), and to methods for the production thereof. Methods and products to identify individuals who are likely to respond in a positive (beneficial) or negative (harmful) manner to drug therapy intended to treat or prevent neuropsychiatric disorders, neurodegeneration, sleep-wake cycles (e.g., including but not limited to Alzheimer's disease, schizophrenia, autism, and attention disorders).
Absstract of: WO2024098003A1
Provided herein are biomarkers present in cell-free DNA (cfDNA) for the early detection of pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD in a subject. The detection of such biomarkers in a subject may be used to inform methods of treating a subject with a therapy (e.g., a drug or biologic) for pre-clinical Alzheimer's Disease (AD), mild cognitive impairment (MCI), or AD. The biomarkers disclosed herein may also be used in methods to monitor the progression of pre-clinical AD, MCI, or AD.
Absstract of: WO2024097164A1
Provided are methods of phosho-tau aggregation-based biomarker discovery, and new utilities for discovered biomarkers in Alzheimer's disease (AD) diagnosis, differentiation, and treatment. Novel p-tau sites, p-tau198, p-tau396, and p-tau422, identified through such methods showed comparable or superior characteristics with established p-tau biomarkers, and identified biomarkers were capable of differentiating AD or mild cognitive impairment (MCI) from cognitively normal controls.
Absstract of: US2024150710A1
Compositions and methods are provided for generation of assembled three-dimensional organoids with defined numbers and ratios of mature neurons and mature glia. Organoids can be assembled from mature neurons and mature glia derived from induced pluripotent stem cells having at least one genetic mutation associated with a neurological disorder, a neurodevelopmental disorder, or a neurodegenerative disease. Such organoids can be used in disease modeling and drug screening. In particular, assembled three-dimensional organoids are provided that model granulin (GRN) loss of function in neurons and astrocytes, which display many of the pathological features of neuronal ceroid lipofusis and frontotemporal dementia.
Absstract of: AU2022348976A1
The invention relates to sets of biomarkers and methods of use thereof for diagnosing, staging, treating, and assessing the response of a treatment for neurocognitive disorders characterized by tau toxicity, such as Alzheimer's disease. Included are at least three locations of phosphorylated peptides, to be used as biomarkers in screening for neurocognitive disorders.
Absstract of: US2024142471A1
Provided is a means for detecting a subject with mild cognitive impairment or assisting in the detection thereof.A biomarker for testing for mild cognitive impairment, comprising Claudin-5.
Absstract of: US2024141033A1
The present invention relates to IL-34 antibodies, compositions comprising the same, and methods of using the antibodies and or compositions thereof for treating immune-mediated diseases such as neurodegenerative diseases, for example Alzheimer's Disease or a tauopathy disease.
Absstract of: US2024141408A1
Described herein are cell-based high-throughput screening (HTS) assays for the identification of activators of γ-secretase.
Absstract of: WO2024087429A1
Use of an antibody for detecting a protein biomarker group in the preparation of a kit for diagnosing Alzheimer's disease (AD), mild cognitive impairment (MCI) and other types of senile dementia. The protein biomarker group comprises a plurality of amyloid precursor protein (APP) fragments as protein biomarkers, and the sequences of the amyloid precursor protein fragments are as shown in SEQ ID NO.1 to SEQ ID NO.7.
Absstract of: WO2024092277A1
The present application provides systems and methods of characterizing and tracking aging, resilience, dementia, and cognitive decline using brain dynamic biomarkers. The methods and system employ advanced signal processing methods to enhance the precision and quality of information coming from the EEG to detect, characterize, or track Alzheimer's Disease (AD) and Related Dementias (ADRD). These digital markers would be relevant in all stages of AD/ AD RD spanning normal cognition, mild cognitive impairment, and AD dementia. The systems and methods include extracting one or more spectral features from EEG signal data using a plurality of state-space models.
Absstract of: US2024142473A1
The present disclosure relates to a method of treating a subject having a proinflammatory endophenotype profile with celecoxib or naproxen to improve cognition or to prevent cognitive decline or dysfunction in the subject. In another aspect, the present disclosure relates to a method of screening a subject for inclusion an NSAID or a PPAR-7 agonist clinical trial. In another aspect, the present disclosure relates to a method of determining a surrogate outcome of an NSAID or a PPAR-7 agonist clinical trial. In yet another aspect, the present disclosure relates to a method of treating an Alzheimer's disease patient having both a proinflammatory endophenotype profile and a metabolic endophenotype profile with a PPAR-7 agonist to improve cognition or to prevent cognitive decline or dysfunction in the patient.
Absstract of: WO2024086630A1
Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed islet amyloid polypeptide (IAPP) isoform or peptide are provided. Methods of detecting IAPP isoforms or peptides are also provided.
Absstract of: WO2024083822A1
In a first aspect the invention relates to a method for identifying a subject suffering from Alzheimer's dementia (AD) or being at risk of developing Alzheimer's dementia, the method comprising: (a) determining in a first body fluid sample of the subject the amount of at least a compound having a mass in gram/mol of 110.0367; (b) determining in a second body fluid sample of the subject the amount of the same compound as in (a); (c) determining the change of the amount of the compound determined according to (a) compared to the respective amount of the compound determined according to (b); (d) analyzing the change as determined in (c) using a computer-implemented prediction algorithm that is capable of predicting AD in a subject based on the compound, whereby a subject suffering from AD or being at risk of developing Alzheimer's dementia is identified if AD is predicted; wherein said first body fluid sample had been obtained prior to administration of thiethylperazine or a pharmaceutically acceptable salt thereof and said second body fluid sample had been obtained after the subject had been administered thiethylperazine or a pharmaceutically acceptable salt thereof.
Absstract of: WO2022265723A1
The disclosure provides compounds, salts and methods of use thereof for the prevention, treatment, delay of onset and management of Alzheimer's disease.
Absstract of: EP4356927A2
The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or nondisease associated forms of tau.
Absstract of: US2021155680A1
The present invention provides an antibody that recognizes peptides the N-terminals of which start from APP669 (collectively referred to as APP669-x) including the peptide APP669-711 related to an amyloid β (Aβ); a method for measuring APP669-x using said antibody; and a sandwich immunoassay method that is capable of detecting and quantifying a polypeptide to be analyzed with a high sensitivity. An APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide. An immunoassay method that uses an APP669-x N-terminal-recognizing monoclonal antibody that specifically recognizes an N-terminal of an APP669-x peptide, and comprises reacting an APP669-x in a sample with the APP669-x N-terminal-recognizing monoclonal antibody to measure the APP669-x.
Nº publicación: JP2024517654A 23/04/2024
Applicant:
アルベルト・アインシュタイン・カレッジ・オブ・メディシン
Absstract of: CA3217225A1
This disclosure provides a method of stabilizing the interaction of a Retinoic Acid Receptor- alpha (RARa) and a corepressor, Nuclear Receptor Corepressor 1 (NCoRl) by contacting the RARa with an amount of a Chaperone Mediated Autophagy (CMA) Activator sufficient to stabilize the RARa-NCoRl interaction. Stabilizing the RARa/ corepressor interaction can prevent a neurodegenerative disorder in a subject at risk for developing the neurodegenerative disorder or slow the advancement of a neurodegenerative disorder in a subject having an early symptom or biomarker of the neurodegenerative disorder. The disclosure also provides a method of maintaining preventing or slowing the advancement of a retinal degenerative disorder in a subject having an early symptom or biomarker of the retinaldegenerative disorder. The neurodegenerative disorder can be Alzheimer's disease (AD),Lewy body dementia, Parkinson's disease (PD), Huntington's disease,.Amyotrophic lateralsclerosis (ALS), Frontotemporal dementia (FTD), Spinocerebellar ataxias (SCAs). The retinal degenerative disorder can be retinitis pigmentosa.